Skip to content

Pharming Group

US · PHAR #3534 by market cap Listed 2020
11.54 -0.63 -5.18%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:01

Price chart

After-hours 11.54 0.00%
14.469.1111.542026-05-262026-11-20
MA5MA10MA20MA60
— MA5 — MA10 — MA20 — MA60
Reader sentiment Are you bullish or bearish on PHAR?

Anonymous reader poll. Unscientific, not investment advice.

✦ StockVane Quant Insights how this is computed

Quant Sentiment Neutral
  • Recent price momentum is -15.1% on average (3-month/1-year).
  • Main-fund capital flow has been a net outflow over the last 45 sessions.
  • Analyst tilt is Buy.
Quant Technical Outlook Neutral
  • Price is below its 20-day average and above its 60-day average.
  • The 20-day average is above the 60-day average, a short-term uptrend.
Quant Rating, last 30 days E → D

Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.

Factor grades

Ranked against 2848 U.S. stocks StockVane covers.

Last computed: 2026-11-21 20:27 UTC

Data coverage: 5 of 6 factors. Missing data is not a zero score.

Overall C

The radar needs all six factors. Available grades are shown below.

Valuation D+

How expensive the stock is versus earnings, sales and its own 5-year history.

P/E (TTM) 35.0x Better than 17%
Forward P/E 31.5x Better than 17%
Price / Sales 2.3x Better than 52%
P/E vs own 5-yr range 77th pctl Better than 29%
Growth B

How fast revenue, profit and free cash flow are compounding.

Revenue CAGR (3Y) 22.3% Better than 84%
Net income CAGR (3Y) -40.7% Better than 7%
Free cash flow CAGR (3Y) 38.1% Better than 79%
Profitability C+

How much profit the business keeps from each dollar of sales and capital.

Gross margin 87.9% Better than 95%
Operating margin 5.6% Better than 36%
Net margin 0.8% Better than 28%
Return on equity 1.1% Better than 30%
Return on invested capital 2.5% Better than 35%
Momentum C

Recent price strength, skipping the latest month to avoid short-term noise.

3-month return -2.6% Better than 68%
6-month return -8.4% Better than 42%
12-month return (ex latest month) -34.4% Better than 7%
Distance below 52-week high 45.9% Better than 23%
Financial Health A-

Balance-sheet strength: leverage, liquidity and interest coverage.

Current ratio 2.6x Better than 68%
Debt to assets 23.2% Better than 51%
Interest coverage 2.2x Better than 38%
Free cash flow / net income 1,892.4% Better than 98%
Analyst View N/A

What the Street thinks: share of Buy ratings and upside to the average target.

Not enough data to grade this factor.

Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.

Performance

1W -8.41%
1M +18.36%
3M -1.20%
6M -10.33%
YTD -34.69%
1Y -28.98%
3Y -0.94%
5Y +33.87%

Key statistics

Price & volume

Prev close
12.17
Open
11.85
Day range
11.30 - 11.97
Avg price
11.75
Volume
10.51K
Turnover
123.40K
Amplitude
5.54%
52-week range
9.11 - 21.34

Valuation

P/E
288.50
P/E (TTM)
34.97
P/B
2.80
EPS
0.04
Net profit
2.83M
Net assets
291.25M

Share structure

Market cap
816.78M
Float cap
803.84M
Shares out
70.78M
Float shares
69.66M

Dividend & listing

Dividend (TTM)
0.00
Listing date
2020-12-23
52-week range 20% of range
9.11 21.34

45.9% below the 52-week high

Trading activity

Net capital flow main funds, last 45 sessions

-266.56K net over the window

Short interest

Shares short
25.78K
As of
2026-10-30

Frequently asked questions

What is the current stock price of Pharming Group (PHAR)?

Pharming Group last traded at 11.54. This page shows a periodic quote snapshot. Check the displayed quote time.

What is Pharming Group's market cap?

About 816.78M.

What is the P/E ratio of Pharming Group?

The trailing twelve-month P/E is 34.97. The Valuation tab shows it against the stock's own five-year range.

Does Pharming Group pay a dividend?

Pharming Group does not currently pay a regular dividend.

Is Pharming Group a buy according to analysts?

The consensus of 2 analysts is a Buy rating, with an average 12-month price target of 39.00, which implies 238.0% upside from the current price. This is not investment advice.

What is Pharming Group's StockVane Quant Rating?

The StockVane Momentum strategy currently rates Pharming Group a D (Sell). Below its 200-day average or in the bottom third on momentum — the strategy is out of it. Not investment advice.

Quote time 2026-11-20 20:01:09 · For reference only, not investment advice and not tailored to your situation.

Pharming Group discussion 0 comments

Add a comment